drugset / Trial / NCT03927690
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
Timeline
- Start
- 2019-05-24
- Primary completion
- 2022-06-17
- Completion
- 2022-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LKA651 | Unknown | 5 mg | Intravitreal |
| Subject | Ranibizumab | Monoclonal antibody | 0.3 mg | Intravitreal |
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |